Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity
Clinical responses to anticancer therapies in advanced soft tissue sarcoma (STS) are unfortunately limited to a small subset of patients. Much of the inter-individual variability in treatment efficacy and risk of toxicities is as result of polymorphisms in genes encoding proteins involved in drug ph...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294222000193 |
| _version_ | 1818232257416003584 |
|---|---|
| author | Elisabetta Gambale Anna Boddi Adriano Pasqui Domenico Andrea Campanacci Guido Scoccianti Ilaria Palchetti Andrea Bernini Lorenzo Antonuzzo Serena Pillozzi |
| author_facet | Elisabetta Gambale Anna Boddi Adriano Pasqui Domenico Andrea Campanacci Guido Scoccianti Ilaria Palchetti Andrea Bernini Lorenzo Antonuzzo Serena Pillozzi |
| author_sort | Elisabetta Gambale |
| collection | DOAJ |
| description | Clinical responses to anticancer therapies in advanced soft tissue sarcoma (STS) are unfortunately limited to a small subset of patients. Much of the inter-individual variability in treatment efficacy and risk of toxicities is as result of polymorphisms in genes encoding proteins involved in drug pharmacokinetics and pharmacodynamics. Therefore, the detection of pharmacogenomics (PGx) biomarkers that might predict drug response and toxicity can be useful to explain the genetic basis for the differences in treatment efficacy and toxicity among STS patients. PGx markers are frequently located in transporters, drug-metabolizing enzyme genes, drug targets, or HLA alleles. Along this line, genetic variability harbouring in the germline genome of the patients can influence systemic pharmacokinetics and pharmacodynamics of the treatments, acting as predictive biomarkers for drug-induced toxicity and treatment efficacy. By linking drug activity to the functional complexity of cancer genomes, also systematic pharmacogenomic profiling in cancer cell lines and primary STS samples represents area of active investigation that could eventually lead to enhanced efficacy and offer a powerful biomarker discovery platform to optimize current treatments and improve the knowledge about the individual's drug response in STS patients into the clinical practice. |
| first_indexed | 2024-12-12T11:03:25Z |
| format | Article |
| id | doaj.art-c438557b8aa444148c519093380f4d5b |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-12-12T11:03:25Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-c438557b8aa444148c519093380f4d5b2022-12-22T00:26:28ZengElsevierCancer Treatment and Research Communications2468-29422022-01-0131100528Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicityElisabetta Gambale0Anna Boddi1Adriano Pasqui2Domenico Andrea Campanacci3Guido Scoccianti4Ilaria Palchetti5Andrea Bernini6Lorenzo Antonuzzo7Serena Pillozzi8Clinical Oncology Unit, Careggi University Hospital, Florence, ItalyDepartment of Health Science, University of Florence, Florence, ItalyMedical Oncology Unit, Careggi University Hospital, Florence, ItalyDepartment of Health Science, University of Florence, Florence, Italy; Department of Orthopaedic Oncology and Reconstructive Surgery, Careggi University Hospital, Florence, ItalyDepartment of Health Science, University of Florence, Florence, ItalyDepartment of Chemistry Ugo Schiff, University of Florence, Sesto Fiorentino, Florence, ItalyDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, Siena, 53100 ItalyClinical Oncology Unit, Careggi University Hospital, Florence, Italy; Medical Oncology Unit, Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, ItalyMedical Oncology Unit, Careggi University Hospital, Florence, Italy; Corresponding author.Clinical responses to anticancer therapies in advanced soft tissue sarcoma (STS) are unfortunately limited to a small subset of patients. Much of the inter-individual variability in treatment efficacy and risk of toxicities is as result of polymorphisms in genes encoding proteins involved in drug pharmacokinetics and pharmacodynamics. Therefore, the detection of pharmacogenomics (PGx) biomarkers that might predict drug response and toxicity can be useful to explain the genetic basis for the differences in treatment efficacy and toxicity among STS patients. PGx markers are frequently located in transporters, drug-metabolizing enzyme genes, drug targets, or HLA alleles. Along this line, genetic variability harbouring in the germline genome of the patients can influence systemic pharmacokinetics and pharmacodynamics of the treatments, acting as predictive biomarkers for drug-induced toxicity and treatment efficacy. By linking drug activity to the functional complexity of cancer genomes, also systematic pharmacogenomic profiling in cancer cell lines and primary STS samples represents area of active investigation that could eventually lead to enhanced efficacy and offer a powerful biomarker discovery platform to optimize current treatments and improve the knowledge about the individual's drug response in STS patients into the clinical practice.http://www.sciencedirect.com/science/article/pii/S2468294222000193Soft tissue sarcomaCancer pharmacogeneticPharmacogenomicsSingle-nucleotide polymorphismsToxicityBiomarker |
| spellingShingle | Elisabetta Gambale Anna Boddi Adriano Pasqui Domenico Andrea Campanacci Guido Scoccianti Ilaria Palchetti Andrea Bernini Lorenzo Antonuzzo Serena Pillozzi Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity Cancer Treatment and Research Communications Soft tissue sarcoma Cancer pharmacogenetic Pharmacogenomics Single-nucleotide polymorphisms Toxicity Biomarker |
| title | Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity |
| title_full | Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity |
| title_fullStr | Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity |
| title_full_unstemmed | Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity |
| title_short | Pharmacogenomics of soft tissue sarcomas: New horizons to understand efficacy and toxicity |
| title_sort | pharmacogenomics of soft tissue sarcomas new horizons to understand efficacy and toxicity |
| topic | Soft tissue sarcoma Cancer pharmacogenetic Pharmacogenomics Single-nucleotide polymorphisms Toxicity Biomarker |
| url | http://www.sciencedirect.com/science/article/pii/S2468294222000193 |
| work_keys_str_mv | AT elisabettagambale pharmacogenomicsofsofttissuesarcomasnewhorizonstounderstandefficacyandtoxicity AT annaboddi pharmacogenomicsofsofttissuesarcomasnewhorizonstounderstandefficacyandtoxicity AT adrianopasqui pharmacogenomicsofsofttissuesarcomasnewhorizonstounderstandefficacyandtoxicity AT domenicoandreacampanacci pharmacogenomicsofsofttissuesarcomasnewhorizonstounderstandefficacyandtoxicity AT guidoscoccianti pharmacogenomicsofsofttissuesarcomasnewhorizonstounderstandefficacyandtoxicity AT ilariapalchetti pharmacogenomicsofsofttissuesarcomasnewhorizonstounderstandefficacyandtoxicity AT andreabernini pharmacogenomicsofsofttissuesarcomasnewhorizonstounderstandefficacyandtoxicity AT lorenzoantonuzzo pharmacogenomicsofsofttissuesarcomasnewhorizonstounderstandefficacyandtoxicity AT serenapillozzi pharmacogenomicsofsofttissuesarcomasnewhorizonstounderstandefficacyandtoxicity |